Metsera (MTSR) Stock Price

Metsera Price

NYSE·CLOSED
70.50
​
Market closed

The consensus 12-month price target for Metsera is 54.57 USD, about 22.6% below where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.

Metsera stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Metsera business model & stock analysis

Metsera Inc. is a clinical stage biopharmaceutical company based in New York City, operating in the Health Care sector with a focus on Biotechnology. The company develops next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for treating obesity and related conditions. Utilizing its proprietary MINT peptide library, HALO half-life extension platform, and MOMENTUM oral delivery system, Metsera has a pipeline including MET-097i, MET-233i, and MET-224o, targeting various obesity treatments with differentiated approaches. Listed on 31 January 2025, the company employs 82 staff.

Frequently asked questions about Metsera

Analysts currently set an average price target of 54.57 USD for the Metsera stock (median: 54.57 USD), implying -22.6 % versus the latest price. The consensus is based on 8 analyst ratings.

9 analysts currently rate the Metsera stock: 7 recommend buying, 2 holding and 0 selling.

Converted at the current exchange rate, the Metsera share trades at 62.98 EUR (70.50 USD).

The revenue cannot currently be calculated for Metsera.

The profit cannot currently be calculated for Metsera.

The P/E ratio cannot be calculated for Metsera at the moment.

The P/S cannot be calculated for Metsera currently.

The Eulerpool Quality Score for Metsera is 2/10.

The ISIN of Metsera is US59267L1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Metsera is MTSR. The ticker symbol is used to trade Metsera shares on the stock exchange.

Fair ValueTerminal
64.86 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website metsera.com
Currency
USD
Initial public offering
Jan 31, 2025
ISIN
US59267L1070
Cusip
59267L107
Market capitalization
7.43 B USDMid Cap
52-Week Range
PEG
-1.65
P/E ratio
P/Ee 2025
-24.84
P/Ee 2028
-18.14
P/Ee 2029
-14.01
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
25.85
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-70.71 %
Last updated Nov 4, 2026, 12:35 AM

Metsera Peer Group

All fundamentals and in-depth analysis of Metsera

Our stock analysis for Metsera stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Metsera. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.